Adding Nivolumab to RT May Reduce BCR Risk in Grade Group 5 Prostate Cancer

Summary: Dealing with high-risk prostate cancer (known as Grade Group 5) is a serious battle. But doctors at the Moffitt Cancer Center have tested a powerful new game plan. Normally, patients receive radiation and hormone therapy. In a new study, doctors added an immune-boosting drug called nivolumab to the mix.

Here is how it works: the hormone therapy acts like a spotlight, drawing the body's defender T-cells to the area. Then, nivolumab steps in to unleash those T-cells to attack the cancer. The results were highly impressive. Over 90% of the men who received this combination were free from the cancer returning after two years, compared to just 75% who had the standard treatment. While there can be some severe side effects, like liver or heart issues, this new combination could be a massive win for men fighting this disease.

For more details, see rssapp-oncologynurseadvisor-com at oncologynurseadvisor.com/news/prostate-cancer-nivolumab-radiotherapy-reduce-bcr-risk-treatment/ (opens in new tab)